Clinical Trial: The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title:

Brief Summary: Protocol is intended to characterize the overall safety and tolerability of eculizumab in this population.

Detailed Summary:
Sponsor: Alexion Pharmaceuticals

Current Primary Outcome: Adverse events and serious adverse events and their severity and relationship to the drug [ Time Frame: 12 weeks ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Alexion Pharmaceuticals

Dates:
Date Received: December 4, 2012
Date Started: May 16, 2012
Date Completion:
Last Updated: March 9, 2017
Last Verified: March 2017